Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
Main Authors: | Daniel V Kalinovsky, Alexey V Kibardin, Irina V Kholodenko, Elena V Svirshchevskaya, Igor I Doronin, Mariya V Konovalova, Maria V Grechikhina, Fedor N Rozov, Sergey S Larin, Sergey M Deyev, Roman V Kholodenko |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/6/e004646.full |
Similar Items
-
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
by: Daniel V. Kalinovsky, et al.
Published: (2023-01-01) -
Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4
by: Daniel V. Kalinovsky, et al.
Published: (2023-10-01) -
Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
by: Irina V. Kholodenko, et al.
Published: (2019-10-01) -
RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype
by: Maxim Sorokin, et al.
Published: (2020-05-01) -
Resistance of Human Liver Mesenchymal Stem Cells to FAS-Induced Cell Death
by: Irina V. Kholodenko, et al.
Published: (2022-07-01)